A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/56 (2006.01) A61K 31/565 (2006.01) A61P 33/02 (2006.01) A61P 33/06 (2006.01) C07J 1/00 (2006.01) C07J 3/00 (2006.01)
Patent
CA 2352205
The invention provides the use of 17-ketosteroid compounds, as well as derivatives, metabolites and precursors of such compounds, and pharmaceutically acceptable salts of any of these compounds, collectively defined herein as the "compounds of the present invention", in the treatment of prevention of hepatitis C type virus and/or hepatitis G type virus in patients in need of such treatment. In addition, the invention provides methods to treat or prevent togavirus infections, including infections by one or more alphaviruses, flaviviruses, such as yellow fever virus, hepatitis C virus and hepatitis G virus, rubella viruses, or pestiviruses, such as bovine virus diarrhea virus. In addition, the invention provides combination therapies including administration of one or more compound of the present invention, as defined herein, and administration of one or more compound selected from plasma concentration-enhancing compounds, macrophage stimulating factor, oxidation agents, ribavirin and alpha interferon, and/or oxygen ventilation. The compounds of the present invention may also be used to ameliorate or reduce one or more symptoms associated with a togavirus infection.
L'invention concerne l'utilisation de composés 17-cétostéroïdes, ainsi que des dérivés, des métabolites et des précurseurs desdits composés, et des sels pharmaceutiquement acceptables de l'un quelconque de ces composés (ci-après appelés collectivement "composés de l'invention") pour le traitement ou la prévention du virus de l'hépatite C et/ou du virus de l'hépatite G chez des patients nécessitant un tel traitement. L'invention concerne en outre des méthodes de traitement ou de prévention d'infections à togavirus, notamment l'infection à un ou plusieurs alphavirus, flavivirus tels que le virus de la fièvre jaune, le virus de l'hépatite C et le virus de l'hépatite G, les virus de la rubéole, les pestivirus tels que le virus de la diarrhée virale des bovins. L'invention concerne enfin des thérapies combinées qui consistent en l'administration d'un ou plusieurs composés de l'invention, tels que définis plus haut, et l'administration d'un ou plusieurs composés choisis parmi des composés facilitant la concentration de plasma, un facteur d'activation des macrophages, des agents d'oxydation, la ribavirine et l'interféron alpha, et/ou la ventilation à l'oxygène. Les composés de l'invention peuvent être également utilisés pour améliorer ou diminuer un ou plusieurs symptômes associés à l'infection à togavirus.
Ahlem Clarence Nathaniel
Frincke James Martin
Prendergast Patrick T.
Hollis-Eden Pharmaceuticals Inc.
Sim & Mcburney
LandOfFree
Use of 17-ketosteroid compounds and derivatives, metabolites... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of 17-ketosteroid compounds and derivatives, metabolites..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of 17-ketosteroid compounds and derivatives, metabolites... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1344351